Table 2 Resistome categories for carbapenem-resistant isolates in our prospective collection

i. Carbapenemases

146

2

98.6%

66.1%

 Allbla_KPC

124

2

98.4%

56.1%

  bla_KPC-3

60

1

98.4%

27.1%

  bla_KPC-2

50

1

98.0%

22.6%

  bla_KPC-4

11

0

100.0%

5.0%

  bla_KPC(read based)^a

3

0

100.0%

1.4%

 AllblaNDM

14

0

100.0%

6.3%

  bla_NDM-1

11

0

100.0%

5.0%

  bla_NDM-5

3

0

100.0%

1.4%

 AllblaSME

6

0

100.0%

2.7%

  bla_SME-1

3

0

100.0%

1.4%

  bla_SME-2

3

0

100.0%

1.4%

 Other carbapenemases

2

0

100.0%

0.9%

  bla_IMP-84andbla_KPC-4

1

0

100.0%

0.5%

  bla_IMP-4

1

0

100.0%

0.5%

ii. ESBL/AmpC + porin defect(s)^b

61

32

65.6%

27.6%

 Includes any ESBL

46

11

80.7%

20.8%

  Includesbla_CTX-M-15

34

2

94.4%

15.4%

  Includesbla_SHV-12

11

5

68.8%

5.0%

  Includes other ESBLs

13

5

72.2%

5.9%

 Includes any AmpC

31

23

57.4%

14.0%

  Includesbla_EC

19

8

70.4%

8.6%

  Includesbla_CMY-2

12

4

75.0%

5.4%

  Includes other AmpCs

5

12

29.4%

2.3%

iii. ESBL/AmpC without porin defect

6

168

3.4%

2.7%

iv. Porin defect(s) without ESBL/AmpC

8

23

25.8%

3.6%

 Defect in both major porins

5

5

50.0%

2.3%

v. No known resistant determinants

0

113

0.0%

0.0%